Abstract
The effectiveness and safety of vaccination of children having chronic inflammatory lung diseses with Pneumo-23 and Act-HIB were evaluated. The group under study included 38 children having chronic pneumonia, congenital defects of lung development, Kartagener's syndrome, mucoviscidosis; of these children, 25 were vaccinated with Pneumo-23 and 13--with Act-HIB. For comparison a group of 40 children with the same pathology, but not vaccinated, was used. A favorable course of the postvaccinal period was noted. Prior to vaccination Streptococcus pneumoniae in association with Haemophilus influenzae were isolated from all patients; in a year after vaccination with Pneumo-23 these microorganisms were isolated only in monoculture: S. pneumoniae in 3 out of 25 cases (88% elimination) and H. influenzae in 10 out of 25 cases (60% elimination).
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adolescent
-
Bacterial Capsules
-
Child
-
Child, Preschool
-
Chronic Disease
-
Haemophilus Infections / microbiology
-
Haemophilus Infections / prevention & control*
-
Haemophilus Vaccines / administration & dosage*
-
Haemophilus influenzae / isolation & purification
-
Humans
-
Pneumococcal Infections / microbiology
-
Pneumococcal Infections / prevention & control*
-
Pneumococcal Vaccines / administration & dosage*
-
Pneumonia, Bacterial / microbiology
-
Pneumonia, Bacterial / prevention & control*
-
Polysaccharides, Bacterial / administration & dosage*
-
Respiratory Tract Infections / microbiology
-
Respiratory Tract Infections / prevention & control*
-
Streptococcus pneumoniae / isolation & purification
-
Vaccines, Acellular / administration & dosage
-
Vaccines, Conjugate / administration & dosage
Substances
-
23-valent pneumococcal capsular polysaccharide vaccine
-
Haemophilus Vaccines
-
Haemophilus influenzae type b polysaccharide vaccine
-
Pneumococcal Vaccines
-
Polysaccharides, Bacterial
-
Vaccines, Acellular
-
Vaccines, Conjugate